Neuroscience:mglu1代谢型谷氨酸受体在兴奋性毒性视网膜变性中的具有重要作用!

2017-09-21 cuiguizhong MedSci原创

意大利罗马大学生理与药理学系的Liberatore F近日在Neuroscience杂志上发表文章称,mGlu1受体在视网膜神经节细胞(RGC)的兴奋性毒性变性中起关键作用。

意大利罗马大学生理与药理学系的Liberatore F近日在Neuroscience杂志上发表文章称,mGlu1受体在视网膜神经节细胞(RGC)的兴奋性毒性变性中起关键作用。

在早产儿视网膜病变、青光眼和年龄相关性黄斑变性等眼部疾病中,神经系统不能受到良好的保护,其特征是视网膜神经节细胞(RGC)死亡。在所有这些疾病中,兴奋性毒性是神经元损伤的主要原因,但是临床数据显示,NMDA受体拮抗剂不适合作为神经保护剂。在这篇文章中,作者研究显示mGlu1代谢型谷氨酸受体的激活促进视网膜神经节细胞(RGC)的兴奋性变性。

他们对出生后第9天的小鼠用具有毒性剂量的谷氨酸钠(MSG,3g / kg)进行处理,发现超过 70%的Brn-3a 阳性的视网膜神经节细胞死亡。 但mGlu1受体阴性变构调节因子(NAM)JNJ16258695(2.5mg/kg,s.c)进行全身给药,发现在很大程度上防止了MSG诱导的视网膜神经节细胞的死亡。同时研究表明,这种治疗没有引起小鼠运动行为的变化。crv4小鼠模型中编码mGlu1受体的基因发生隐性突变,因此,他们还将MSG注射到缺乏mGlu1受体的crv4小鼠模型中,发现MSG在crv4小鼠中不引起视网膜变性,而在同窝出生的野生型小鼠中具有毒性活性。

这些研究结果表明,mGlu1受体在视网膜神经节细胞(RGC)的兴奋性毒性变性中起关键作用。这项研究也表明,需要进一步在视网膜神经变性模型中研究mGlu1受体NAMs的作用。

原文出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747095, encodeId=12111e470959b, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Tue Aug 21 02:50:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041067, encodeId=c3a8204106e93, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Aug 04 04:50:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023491, encodeId=03f62023491cf, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Nov 19 17:50:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269951, encodeId=0829126995132, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364235, encodeId=f3b11364235f5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375689, encodeId=068113e5689d5, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463560, encodeId=e3fe14635600b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747095, encodeId=12111e470959b, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Tue Aug 21 02:50:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041067, encodeId=c3a8204106e93, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Aug 04 04:50:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023491, encodeId=03f62023491cf, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Nov 19 17:50:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269951, encodeId=0829126995132, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364235, encodeId=f3b11364235f5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375689, encodeId=068113e5689d5, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463560, encodeId=e3fe14635600b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747095, encodeId=12111e470959b, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Tue Aug 21 02:50:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041067, encodeId=c3a8204106e93, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Aug 04 04:50:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023491, encodeId=03f62023491cf, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Nov 19 17:50:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269951, encodeId=0829126995132, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364235, encodeId=f3b11364235f5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375689, encodeId=068113e5689d5, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463560, encodeId=e3fe14635600b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747095, encodeId=12111e470959b, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Tue Aug 21 02:50:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041067, encodeId=c3a8204106e93, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Aug 04 04:50:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023491, encodeId=03f62023491cf, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Nov 19 17:50:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269951, encodeId=0829126995132, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364235, encodeId=f3b11364235f5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375689, encodeId=068113e5689d5, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463560, encodeId=e3fe14635600b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
    2017-09-23 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747095, encodeId=12111e470959b, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Tue Aug 21 02:50:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041067, encodeId=c3a8204106e93, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Aug 04 04:50:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023491, encodeId=03f62023491cf, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Nov 19 17:50:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269951, encodeId=0829126995132, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364235, encodeId=f3b11364235f5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375689, encodeId=068113e5689d5, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463560, encodeId=e3fe14635600b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
    2017-09-23 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1747095, encodeId=12111e470959b, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Tue Aug 21 02:50:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041067, encodeId=c3a8204106e93, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Aug 04 04:50:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023491, encodeId=03f62023491cf, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Nov 19 17:50:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269951, encodeId=0829126995132, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364235, encodeId=f3b11364235f5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375689, encodeId=068113e5689d5, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463560, encodeId=e3fe14635600b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
    2017-09-23 jichang
  7. [GetPortalCommentsPageByObjectIdResponse(id=1747095, encodeId=12111e470959b, content=<a href='/topic/show?id=76a090e5544' target=_blank style='color:#2F92EE;'>#视网膜变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90755, encryptionId=76a090e5544, topicName=视网膜变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6db35920976, createdName=circumcision, createdTime=Tue Aug 21 02:50:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041067, encodeId=c3a8204106e93, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Aug 04 04:50:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023491, encodeId=03f62023491cf, content=<a href='/topic/show?id=57ce9605ef6' target=_blank style='color:#2F92EE;'>#重要作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96057, encryptionId=57ce9605ef6, topicName=重要作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Nov 19 17:50:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269951, encodeId=0829126995132, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364235, encodeId=f3b11364235f5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375689, encodeId=068113e5689d5, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463560, encodeId=e3fe14635600b, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Sat Sep 23 12:50:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
    2017-09-23 huangdf

相关资讯

徐国彤:视网膜下腔移植不同干细胞对大鼠视网膜变性的干预作用

11月06日,由生物谷主办的2015(第七届)干细胞技术与临床转化论坛在上海君衡城市酒店举行。来自同济大学医学院的徐国彤院长在会议上发表了题为"视网膜下腔移植不同干细胞对大鼠视网膜变性的干预作用"的精彩报告。 视网膜变性是以年龄相关性黄斑变性和视网膜色素变性为主的致盲眼病,在全球范围内属于最严重的眼部疾病之一。而近些年来应用视网膜下腔移植干细胞治疗视网膜变性在动物研究和临床试验中都取得了一定

Stem Cell Reports:失明或许有救啦:干细胞来帮您!

因终末期视网膜变性而失明的人数正在稳步上升,且目前这种病情无法逆转。然而,一项具有突破性的研究,使用干细胞技术让人们似乎看到了一线光明。晚期视网膜变性包括老年性黄斑变性和色素性视网膜炎等疾病。这是导致老年人发生不可逆性视力丧失和失明最常见原因。在此类疾病中,眼部对光敏感的细胞核层退化导致视力逐渐恶化。随着美国人口开始进入老龄化,视网膜变性的患病率逐渐在增加。例如,在 2000-2010 年间,老年

Science:HIV药物可以用来治疗失明?

文字说明: 治疗艾滋病的药物可以用来治疗失明吗? 资料来源: Bradley D. Gelfand 一项在小鼠中的研究显示,一类被称作核苷逆转录酶抑制剂(NRTIs)的大众化HIV药物可有效地治疗诸如视网膜变性及移植物抗宿主病等疾病。据研究人员披露,该类药物的这些先前未被认识到的治疗裨益与他们阻断HIV中的逆转录能力——这是一种可阻止该病毒从其基因组进行复制的作用——无关,